[go: up one dir, main page]

PL377735A1 - Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń - Google Patents

Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Info

Publication number
PL377735A1
PL377735A1 PL377735A PL37773504A PL377735A1 PL 377735 A1 PL377735 A1 PL 377735A1 PL 377735 A PL377735 A PL 377735A PL 37773504 A PL37773504 A PL 37773504A PL 377735 A1 PL377735 A1 PL 377735A1
Authority
PL
Poland
Prior art keywords
ylmethoxy
oxazol
cyclohexyloxy
atherosclerosis
phenyl
Prior art date
Application number
PL377735A
Other languages
English (en)
Inventor
Christian Stapper
Heiner Glombik
Eugen Falk
Jochen Goerlitzer
Dirk Gretzke
Stefanie Keil
Hans-Ludwig Schaefer
Wolfgang Wendler
Original Assignee
Sanofi-Aventis Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh
Publication of PL377735A1 publication Critical patent/PL377735A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL377735A 2003-02-27 2004-02-19 Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń PL377735A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10308355A DE10308355A1 (de) 2003-02-27 2003-02-27 Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PL377735A1 true PL377735A1 (pl) 2006-02-20

Family

ID=32920629

Family Applications (3)

Application Number Title Priority Date Filing Date
PL377735A PL377735A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378437A PL378437A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378130A PL378130A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL378437A PL378437A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-metylo-2-(3-(2-fenylooksazol-4-ilometoksy)-cykloheksanokarbonyloamino)-masłowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
PL378130A PL378130A1 (pl) 2003-02-27 2004-02-19 Pochodne kwasu 3-(2-fenylooksazol-4-ilometoksy)-cykloheksylometoksyoctowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń

Country Status (34)

Country Link
US (5) US7335671B2 (pl)
EP (3) EP1599455B1 (pl)
JP (3) JP2006519193A (pl)
KR (3) KR20050105492A (pl)
CN (3) CN100439347C (pl)
AR (3) AR043432A1 (pl)
AT (3) ATE430738T1 (pl)
AU (3) AU2004215672B2 (pl)
BR (3) BRPI0407758A (pl)
CA (3) CA2517386A1 (pl)
CL (2) CL2004000391A1 (pl)
CO (2) CO5690578A2 (pl)
DE (4) DE10308355A1 (pl)
DK (3) DK1599452T3 (pl)
EC (2) ECSP055986A (pl)
ES (3) ES2326418T3 (pl)
HR (3) HRP20050744A2 (pl)
IL (2) IL170316A (pl)
MA (3) MA27736A1 (pl)
MX (3) MXPA05008951A (pl)
NO (3) NO20054398L (pl)
OA (2) OA13035A (pl)
PA (1) PA8596801A1 (pl)
PE (3) PE20040959A1 (pl)
PL (3) PL377735A1 (pl)
PT (3) PT1599452E (pl)
RS (1) RS20050594A (pl)
RU (3) RU2005129995A (pl)
SA (1) SA04250153A (pl)
TN (2) TNSN05204A1 (pl)
TW (3) TW200508210A (pl)
UY (2) UY28210A1 (pl)
WO (3) WO2004076427A1 (pl)
ZA (2) ZA200505765B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) * 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) * 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039533B4 (de) * 2004-08-14 2006-09-28 Sanofi-Aventis Deutschland Gmbh Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039532B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039509B4 (de) 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004060227B3 (de) 2004-12-15 2006-07-20 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) * 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
WO2007039177A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
AU2006347121B2 (en) 2006-08-10 2013-06-06 Acacia-No-Ki Co., Ltd. Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
CN101801906A (zh) 2007-08-16 2010-08-11 索尔维公司 制备4-氟取代的3-氧代-烷酸酯的方法
PT2246343T (pt) 2008-02-29 2016-08-05 Nissan Chemical Ind Ltd Processo de produção de composto de tiofeno e seu intermediário
US7615661B2 (en) * 2008-03-12 2009-11-10 International Flavors & Fragrances Inc. Thioester compounds and their use in fragrance or flavor applications
ES2932091T3 (es) 2017-12-13 2023-01-11 Canon Kk Cartucho y dispositivo de formación de imágenes
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr) * 1990-06-19 1992-09-11 Commissariat Energie Atomique Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en) 1993-02-15 1998-07-15 Wellcome Found History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
UA64713C2 (uk) 1996-12-31 2004-03-15 Reddys Lab Ltd Dr Похідні азолідиндіону, спосіб їх одержання (варіанти), фармацевтичні композиції на їх основі, спосіб попередження або лікування, спосіб зниження рівня глюкози і проміжна сполука
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
KR20010021936A (ko) 1997-07-16 2001-03-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 융합된 1,2,4-티아디아진 유도체, 그의 제조와 사용
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
WO2000012491A1 (fr) * 1998-08-27 2000-03-09 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments dont ils sont le principe actif
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
US6908926B1 (en) * 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
HUP0200997A3 (en) * 1999-04-28 2003-03-28 Sanofi Aventis Deutschland Tri-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
CA2371271A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
ES2265952T3 (es) 1999-06-18 2007-03-01 MERCK & CO., INC. Derivados de ariltiazolidindiona y ariloxazolidindiona.
US6413737B1 (en) 1999-07-09 2002-07-02 Cohesion Technologies, Inc. Ecarin prothrombin protease and methods
MXPA02000973A (es) 1999-07-29 2002-07-30 Lilly Co Eli Benzofurilpiperazinas y benzofurilhomopiperazinas: agonistas de serotonina.
KR20020033778A (ko) * 1999-09-01 2002-05-07 로버트 흐라이탁, 미쉘 베스트 설포닐 카복스아미드 유도체, 이의 제조방법 및약제로서의 이의 용도
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
PL357118A1 (pl) 1999-12-03 2004-07-12 Astrazeneca Ab Postać krystaliczna kwasu (S)-2-etoksy-3-[4-(2-{4-metanosulfonyloksyfenylo} etoksy) fenylo] propanowego
WO2001072290A2 (en) 2000-03-31 2001-10-04 Probiodrug Ag Method for the improvement of islet signaling in diabetes mellitus and for its prevention
KR20030007548A (ko) 2000-04-25 2003-01-23 교린 세이야꾸 가부시키 가이샤 티아졸리딘디온 유도체의 신규한 안정한 결정 및 이의제조방법
CA2407538C (en) 2000-04-28 2007-01-09 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
AU2001259592B2 (en) 2000-05-11 2005-02-24 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
CZ20024003A3 (cs) * 2000-06-09 2003-03-12 Aventis Pharma Deutschland Gmbh Deriváty acylfenylmočoviny, způsoby jejich výroby a použití jako léčiva
DE10038709A1 (de) 2000-08-09 2002-02-28 Aventis Pharma Gmbh Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) * 2000-08-11 2002-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
DE60128239T2 (de) * 2000-08-23 2008-01-10 Eli Lilly And Co., Indianapolis Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE60129712T2 (de) 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
TWI243162B (en) 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
ES2277890T3 (es) 2000-12-21 2007-08-01 Sanofi-Aventis Deutschland Gmbh Nuevas difenilazetidinonas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para el tratamiento de trastornos del metabolismo de lipidos.
MXPA03005763A (es) * 2000-12-25 2004-05-03 Ono Pharmaceutical Co Compuestos derivados de dihidronaftaleno y agente que comprende el derivado como ingrediente activo.
JP2004529097A (ja) * 2001-02-15 2004-09-24 ファイザー・プロダクツ・インク Ｐｐａｒアゴニスト
PE20021091A1 (es) 2001-05-25 2003-02-04 Aventis Pharma Gmbh Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
CZ20033328A3 (cs) * 2001-06-07 2004-06-16 Eli Lilly And Company Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR)
DE10154689A1 (de) 2001-11-09 2003-05-22 Probiodrug Ag Substituierte Aminoketonverbindungen
WO2003004458A1 (en) 2001-07-03 2003-01-16 Biovitrum Ab New compounds
FR2827859B1 (fr) 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
CA2458210C (en) 2001-08-31 2011-09-20 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar-activators
ATE433440T1 (de) 2002-02-05 2009-06-15 Lilly Co Eli Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
DE10215908B4 (de) 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de) 2002-04-11 2003-11-06 Aventis Pharma Gmbh Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de) 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
HRP20050744A2 (en) 2006-09-30
PE20050292A1 (es) 2005-05-24
ECSP055985A (es) 2006-01-16
DK1599452T3 (da) 2007-10-01
MXPA05008995A (es) 2005-10-18
EP1599455A1 (de) 2005-11-30
CN1753879A (zh) 2006-03-29
HRP20050742A2 (en) 2006-09-30
CL2004000391A1 (es) 2005-01-07
DE502004004139D1 (de) 2007-08-02
ZA200505765B (en) 2006-05-31
AU2004215673A1 (en) 2004-09-10
CL2004000392A1 (es) 2005-04-22
IL170314A (en) 2010-11-30
NO20054398L (no) 2005-11-02
MXPA05008951A (es) 2005-11-04
TW200508210A (en) 2005-03-01
US7872034B2 (en) 2011-01-18
JP2006519194A (ja) 2006-08-24
SA04250153A (ar) 2005-12-03
US20050215596A1 (en) 2005-09-29
PE20040959A1 (es) 2005-01-17
ATE435217T1 (de) 2009-07-15
CN1756748A (zh) 2006-04-05
EP1599453B1 (de) 2009-05-06
OA13035A (en) 2006-11-10
JP2006519193A (ja) 2006-08-24
KR20050105492A (ko) 2005-11-04
NO20054396D0 (no) 2005-09-22
PT1599453E (pt) 2009-07-14
CN100439347C (zh) 2008-12-03
DK1599455T3 (da) 2009-11-09
CO5690580A2 (es) 2006-10-31
KR20050106462A (ko) 2005-11-09
PT1599452E (pt) 2007-09-12
WO2004076427A1 (de) 2004-09-10
CN1753881A (zh) 2006-03-29
NO20054408L (no) 2005-11-23
PA8596801A1 (es) 2004-09-16
CN100398526C (zh) 2008-07-02
ES2326418T3 (es) 2009-10-09
US20080015238A1 (en) 2008-01-17
AR043427A1 (es) 2005-07-27
US20040209920A1 (en) 2004-10-21
US7259177B2 (en) 2007-08-21
AU2004215673B2 (en) 2009-10-01
RU2005130002A (ru) 2006-01-27
MXPA05008988A (es) 2005-10-18
BRPI0407758A (pt) 2006-02-14
PT1599455E (pt) 2009-09-29
EP1599455B1 (de) 2009-07-01
BRPI0407814A (pt) 2006-02-14
AU2004215677B2 (en) 2010-01-07
NO20054408D0 (no) 2005-09-22
CO5690578A2 (es) 2006-10-31
CA2517381A1 (en) 2004-09-10
CA2517386A1 (en) 2004-09-10
TNSN05206A1 (en) 2007-06-11
WO2004076426A1 (de) 2004-09-10
HRP20050743A2 (en) 2006-08-31
IL170316A (en) 2010-11-30
DE502004009453D1 (de) 2009-06-18
AU2004215672B2 (en) 2010-01-07
AR043432A1 (es) 2005-07-27
CA2516620A1 (en) 2004-09-10
EP1599453A1 (de) 2005-11-30
US7335671B2 (en) 2008-02-26
BRPI0407907A (pt) 2006-02-14
ATE365159T1 (de) 2007-07-15
JP2006519199A (ja) 2006-08-24
WO2004076428A1 (de) 2004-09-10
PE20050293A1 (es) 2005-05-24
DE10308355A1 (de) 2004-12-23
ES2329366T3 (es) 2009-11-25
NO20054398D0 (no) 2005-09-22
AU2004215672A1 (en) 2004-09-10
AU2004215677A1 (en) 2004-09-10
EP1599452B1 (de) 2007-06-20
RU2005129995A (ru) 2006-01-27
OA13034A (en) 2006-11-10
DK1599453T3 (da) 2009-08-24
UY28209A1 (es) 2004-09-30
TW200510352A (en) 2005-03-16
TW200500349A (en) 2005-01-01
PL378437A1 (pl) 2006-04-03
NO20054396L (no) 2005-11-11
UY28210A1 (es) 2004-09-30
AR043433A1 (es) 2005-07-27
ZA200505768B (en) 2005-11-23
CN100439345C (zh) 2008-12-03
PL378130A1 (pl) 2006-03-06
ATE430738T1 (de) 2009-05-15
RU2005129992A (ru) 2006-02-10
US7365084B2 (en) 2008-04-29
ES2287700T3 (es) 2007-12-16
RS20050594A (en) 2007-12-31
TNSN05204A1 (en) 2007-06-11
MA27736A1 (fr) 2006-02-01
US20050101637A1 (en) 2005-05-12
MA27742A1 (fr) 2006-02-01
EP1599452A1 (de) 2005-11-30
ECSP055986A (es) 2006-01-16
US20080167354A1 (en) 2008-07-10
MA27737A1 (fr) 2006-02-01
KR20050106461A (ko) 2005-11-09
DE502004009690D1 (de) 2009-08-13

Similar Documents

Publication Publication Date Title
PL377735A1 (pl) Pochodne kwasu 4-(3-(2-fenylooksazol-4-ilometoksy)- cykloheksyloksy)- propano-1-karboksylowego i związki pokrewne, jako modulatory PPAR do leczenia cukrzycy typu 2 i stwardnienia naczyń
HUS1700047I1 (hu) Új gyógyszerészeti készítmény, amely tartalmaz 4-(4-(3-(4-klór-3-trifluormetil-fenil)-ureido)-3-fluor-fenoxi)-piridin-2-karbonsavat, hiperproliferatív rendellenességek kezelésére
RS56194B1 (sr) Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja
NO20062030L (no) Derivater av N-heterocyklylmetylbenzamider, fremgangsmate for fremstilling derav og anvendelse av forbindelsene t terapeutiske midler.
PL1848700T3 (pl) Sole kwasu (s)-2-amino-3-{4-[4-(2,4-diokso-tiazolidyn-5-ylometylo)- fenoksy]-fenylo}-propionowego i jego estrów metylowych jako inhibitory interleukiny do leczenia otyłości lub cukrzycy
AU2006336504A8 (en) 1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
WO2005105739A3 (en) Cyanopyrrole containing cyclic carbamate and thiocarbamate biaryls and methods for preparing the same
AU2034601A (en) Crystalline form of 3-(4-(2-(4-tert-butoxycarbonylaminophenyl)ethoxy)phenyl)-(s) 2-ethoxy propanoic acid
HUP9800511A3 (en) Phosphorylized derivatives of 4-{4-[4-(hydroxy-diphenyl)-1-pipe
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
PL1644340T3 (pl) N-[({4-podstawione związki piperazyn-1-ylo}sulfonylometylo)alkilo]-n-hydroksyformamidowe jako inhibitory metaloproteinazy
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
ATE366576T1 (de) Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
IL181010A0 (en) 2-{3,'2- (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes
AU2003292449A1 (en) Process for the preparation of 3-(2-(3,4-dimethoxybenzoyl)-4,5- dimethoxyphenyl) -pentan-2-one
ZA200601986B (en) Process for the synthesis of 3-(3-fluoro-4-hydroxyphenyl)-7-hydroxynaphthonitrile
WO2005037756A3 (fr) Nouveaux procedes de preparation de l’acide 4-[4-(4-methoxymethoxy-4’-methyl-biphenyl-2-yl)-but-3-ene-(e)-1-ynyl]-benzoïque

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)